For instance, the human epidermal growth factor receptor-2 (HER-2/ErbB-2) is over-expressed in 25–30% of breast and ovarian cancers and has been broadly utilized as a target for passive immunotherapeutical interventions [1] in particular with the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) [2]. Here, ERBB2 is linked to ovarian cancer.